<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41006954</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1759-7714</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>18</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Thoracic cancer</Title><ISOAbbreviation>Thorac Cancer</ISOAbbreviation></Journal><ArticleTitle>Trastuzumab Deruxtecan-Induced Myotoxicity: First Case Report About Myopathy in Patient With Normal Body Composition and Clinical Insights.</ArticleTitle><Pagination><StartPage>e70168</StartPage><MedlinePgn>e70168</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70168</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/1759-7714.70168</ELocationID><Abstract><AbstractText>Trastuzumab deruxtecan (T-DXd) significantly improves outcomes in HER2-positive or low metastatic breast cancer (MBC), but systematic documentation of its myotoxicity is lacking. A 45-year-old woman with HER2-low MBC and normal body composition (BMI 22.9&#x2009;kg/m<sup>2</sup>, visceral adipose area [VAT] 69.1&#x2009;cm<sup>2</sup>) developed T-DXd myopathy. She experienced dysphagia, Grade III myalgia, and creatine kinase (CK) peak of 1755&#x2009;U/L, with MRI confirming lumbar subcutaneous edema and paraspinal muscle swelling. T-DXd was discontinued. Supportive therapy included hydration, urine alkalization by sodium bicarbonate, glutathione, and magnesium isoglycyrrhizinate. By Day 8, CK decreased to 539&#x2009;U/L with myalgia improvement. After 13&#x2009;days off therapy, CK rebounded to 1735&#x2009;U/L with Grade III myalgia, which resolved upon reinitiating support. This case report presents the first documented instance of severe T-DXd-related myopathy in a patient with normal body composition. The observed case outcomes suggest that the combination of glutathione and magnesium isoglycyrrhizinate could potentially reduce CK levels and alleviate T-DXd-associated muscle pain. However, the observed clinical efficacy is based on an individual case. Extrapolation of these clinical outcomes requires large-scale randomized controlled trials with rigorous covariate adjustment.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Thoracic Cancer published by John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>LiuDan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dai</LastName><ForeName>ShuHui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nursing, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>LiTong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital Infection Control Department, Zhuhai Center For Maternal and Child Health Care (Zhuhai Women and Children's Hospital), Zhuhai, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2220009000242</GrantID><Agency>2023 Zhuhai Medical Research Project</Agency><Country/></Grant><Grant><GrantID>2420004000202</GrantID><Agency>Zhuhai Science and Technology Plan Project in the Field of Social Development</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Thorac Cancer</MedlineTA><NlmUniqueID>101531441</NlmUniqueID><ISSNLinking>1759-7706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P188ANX8CK</RegistryNumber><NameOfSubstance UI="D000068878">Trastuzumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074322">Antineoplastic Agents, Immunological</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068878" MajorTopicYN="Y">Trastuzumab</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081030" MajorTopicYN="Y">Myotoxicity</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001823" MajorTopicYN="N">Body Composition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009135" MajorTopicYN="Y">Muscular Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074322" MajorTopicYN="Y">Antineoplastic Agents, Immunological</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">creatine kinase</Keyword><Keyword MajorTopicYN="N">glutathione</Keyword><Keyword MajorTopicYN="N">magnesium isoglycyrrhizinate</Keyword><Keyword MajorTopicYN="N">myotoxicity</Keyword><Keyword MajorTopicYN="N">trastuzumab deruxtecan</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41006954</ArticleId><ArticleId IdType="pmc">PMC12474558</ArticleId><ArticleId IdType="doi">10.1111/1759-7714.70168</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hurvitz S. A., Hegg R., Chung W. P., et&#xa0;al., &#x201c;Trastuzumab Deruxtecan Versus Trastuzumab Emtansine in Patients With HER2&#x2010;Positive Metastatic Breast Cancer: Updated Results From DESTINY&#x2010;Breast03, a Randomised, Open&#x2010;Label, Phase 3 Trial,&#x201d; Lancet 401, no. 10371 (2023): 105&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">36495879</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T., Sohn J. H., Tokunaga E., et&#xa0;al., &#x201c;Trastuzumab Deruxtecan Versus Treatment of Physician's Choice in Previously Treated Asian Patients With HER2&#x2010;Low Unresectable/Metastatic Breast Cancer:Subgroup Analysis of the DESTINY&#x2010;Breast04 Study,&#x201d; Breast Cancer 31, no. 5 (2024): 858&#x2013;868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11341650</ArticleId><ArticleId IdType="pubmed">38884900</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogitani Y., Aida T., Hagihara K., et&#xa0;al., &#x201c;DS&#x2010;8201a, A Novel HER2&#x2010;Targeting ADC With a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy With Differentiation From T&#x2010;DM1,&#x201d; Clinical Cancer Research 22, no. 20 (2016): 5097&#x2013;5108.</Citation><ArticleIdList><ArticleId IdType="pubmed">27026201</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Guo D., Jiang Z., et&#xa0;al., &#x201c;Novel HER2&#x2010;Targeting Antibody&#x2010;Drug Conjugates of Trastuzumab Beyond T&#x2010;DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS&#x2010;8201a) and (Vic&#x2010;)trastuzumab Duocarmazine (SYD985),&#x201d; European Journal of Medicinal Chemistry 183 (2019): 111682.</Citation><ArticleIdList><ArticleId IdType="pubmed">31563805</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakada T., Sugihara K., Jikoh T., Abe Y., and Agatsuma T., &#x201c;The Latest Research and Development Into the Antibody&#x2010;Drug Conjugate,[Fam&#x2010;]Trastuzumab Deruxtecan (DS&#x2010;8201a),for HER2 Cancer Therapy,&#x201d; Chemical &amp; Pharmaceutical Bulletin (Tokyo) 67, no. 3 (2019): 173&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">30827997</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares L. R., Vilbert M., Rosa V., et&#xa0;al., &#x201c;Incidence of Interstitial Lung Disease and Cardiotoxicity With Trastuzumab Deruxtecan in Breast Cancer Patients: A Systematic Review and Single&#x2010;Arm Meta&#x2010;Analysis,&#x201d; ESMO Open 8, no. 4 (2023): 101613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10485391</ArticleId><ArticleId IdType="pubmed">37481956</ArticleId></ArticleIdList></Reference><Reference><Citation>Loganathan P., Oddis C. V., and Aggarwal R., &#x201c;Immune&#x2010;Mediated Statin Myopathy,&#x201d; Expert Review of Clinical Immunology 12, no. 1 (2016): 33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">26515829</ArticleId></ArticleIdList></Reference><Reference><Citation>Sieb J. P. and Gillessen T., &#x201c;Iatrogenic and Toxic Myopathies,&#x201d; Muscle &amp; Nerve 27, no. 2 (2003): 142&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">12548521</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohassel P. and Mammen A. L., &#x201c;Anti&#x2010;HMGCR Myopathy,&#x201d; Journal of Neuromuscular Diseases 5, no. 1 (2018): 11&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5836404</ArticleId><ArticleId IdType="pubmed">29480216</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakour N., Moriarty F., Moore G., Robson T., and Annett S. L., &#x201c;Prognostic Significance of Glucocorticoid Receptor Expression in Cancer: A Systematic Review and Meta&#x2010;Analysis,&#x201d; Cancers 13, no. 7 (2021): 1649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8037088</ArticleId><ArticleId IdType="pubmed">33916028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wekking D., Porcu M., Pellegrino B., et&#xa0;al., &#x201c;Multidisciplinary Clinical Guidelines in Proactive Monitoring, Early Diagnosis, and Effective Management of Trastuzumab Deruxtecan (T&#x2010;DXd)&#x2010;Induced Interstitial Lung Disease (ILD) in Breast Cancer Patients,&#x201d; ESMO Open 8, no. 6 (2023): 102043.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10679891</ArticleId><ArticleId IdType="pubmed">37951130</ArticleId></ArticleIdList></Reference><Reference><Citation>Zardavas D., Suter T. M., Van Veldhuisen D. J., et&#xa0;al., &#x201c;Role of Troponins I and T and N&#x2010;Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early&#x2010;Stage Human Epidermal Growth Factor Receptor 2&#x2010;Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy,&#x201d; Journal of Clinical Oncology 35, no. 8 (2017): 878&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">28199174</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdain H., Di Meglio A., Mansouri I., et&#xa0;al., &#x201c;Use and Outcomes of Trastuzumab Deruxtecan in HER2&#x2010;Positive and HER2&#x2010;Low Metastatic Breast Cancer in a Real&#x2010;World Setting: A Nationwide Cohort Study,&#x201d; ESMO Open 9, no. 12 (2024): 104083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11697054</ArticleId><ArticleId IdType="pubmed">39662227</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammarsten O., Fu M. L., Sigurjonsdottir R., et&#xa0;al., &#x201c;Troponin T Percentiles From a Random Population Sample, Emergency Room Patients and Patients With Myocardial Infarction,&#x201d; Clinical Chemistry 58, no. 3 (2012): 628&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pubmed">22258764</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh J. and Amato A. A., &#x201c;Management of Immune&#x2010;Mediated Necrotizing Myopathy,&#x201d; Muscle &amp; Nerve 70, no. 2 (2024): 166&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">38801022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane R. J. and Mastaglia F. L., &#x201c;Drug&#x2010;Induced Myopathies in Man,&#x201d; Lancet 2, no. 8089 (1978): 562&#x2013;566.</Citation><ArticleIdList><ArticleId IdType="pubmed">79927</ArticleId></ArticleIdList></Reference><Reference><Citation>Munday R., &#x201c;Oxidation of Glutathione and Reduced Pyridine Nucleotides by the Myotoxic and Mutagenic Aromatic Amine, 1,2,4&#x2010;Triaminobenzene,&#x201d; Chemico&#x2010;Biological Interactions 62, no. 2 (1987): 131&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">3594637</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S., Costa R., di Federico A., et&#xa0;al., &#x201c;Histopathological Evidence for a Non&#x2010;Inflammatory Mechanism in Osimertinib&#x2010;Induced Myopathy: A Case Report,&#x201d; Journal of Thoracic Oncology 19, no. 9 (2024): 1352&#x2013;1355.</Citation><ArticleIdList><ArticleId IdType="pubmed">38912994</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaszewski M., Stepien K. M., Tomaszewska J., et&#xa0;al., &#x201c;Statin&#x2010;Induced Myopathies,&#x201d; Pharmacological Reports 63, no. 4 (2011): 859&#x2013;866.</Citation><ArticleIdList><ArticleId IdType="pubmed">22001973</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Z., Chen Y., and Zhang Y., &#x201c;Mitochondrial Reactive Oxygen Species Cause Major Oxidative Mitochondrial DNA Damages and Repair Pathways,&#x201d; Journal of Biosciences 45 (2020): 84.</Citation><ArticleIdList><ArticleId IdType="pubmed">32661211</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx C., Sonnemann J., Maddocks O., et&#xa0;al., &#x201c;Global Metabolic Alterations in Colorectal Cancer Cells During Irinotecan&#x2010;Induced DNA Replication Stress,&#x201d; Cancer &amp; Metabolism 10, no. 1 (2022): 10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9251592</ArticleId><ArticleId IdType="pubmed">35787728</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolova B., Semkova S., Tsoneva I., et&#xa0;al., &#x201c;Redox&#x2010;Related Molecular Mechanism of Sensitizing Colon Cancer Cells to Camptothecin Analog SN38,&#x201d; Anticancer Research 40, no. 9 (2020): 5159&#x2013;5170.</Citation><ArticleIdList><ArticleId IdType="pubmed">32878804</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C. I., Chen Y. C., Kao Y. K., et&#xa0;al., &#x201c;Taurine Protects Irinotecan&#x2010;Induced Muscle Dysfunction by Modulating Oxidative Stress and Endoplasmic Reticulum Stress in Human Skeletal Muscle Cells,&#x201d; Anticancer Research 44, no. 12 (2024): 5371&#x2013;5378.</Citation><ArticleIdList><ArticleId IdType="pubmed">39626917</ArticleId></ArticleIdList></Reference><Reference><Citation>
Pubchem
, &#x201c;1&#x2010;[(2R,3aS,7aS)&#x2010;2&#x2010;(5&#x2010;Methyl&#x2010;1,2,4&#x2010;Oxadiazol&#x2010;3&#x2010;yl)&#x2010;3,3a,4,5,7,7a&#x2010;Hexahydro&#x2010;2H&#x2010;furo[2,3&#x2010;c]pyridin&#x2010;6&#x2010;yl]&#x2010;2&#x2010;(5&#x2010;Fluoropyridin&#x2010;2&#x2010;yl)Ethanone,&#x201d; 2025, https://pubchem.ncbi.nlm.nih.gov/compound/131682096.</Citation></Reference><Reference><Citation>Ouyang Q., Chen Q., Ke S., et&#xa0;al., &#x201c;Rab8a as a Mitochondrial Receptor for Lipid Droplets in Skeletal Muscle,&#x201d; Developmental Cell 58, no. 4 (2023): 289&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pubmed">36800997</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Jia F., Li J., et&#xa0;al., &#x201c;Sprayable Reactive Oxygen Species&#x2010;Responsive Hydrogel Coatings Restore Endothelial Barrier Integrity for Functional Vascular Healing,&#x201d; ACS Nano 19 (2025): 21757&#x2013;21774.</Citation><ArticleIdList><ArticleId IdType="pubmed">40457543</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaacobi P. S., Kessner R., Bar Y., et&#xa0;al., &#x201c;Body Composition Metrics as a Determinant of Trastuzumab Deruxtecan Related Toxicity and Response,&#x201d; npj Breast Cancer 11, no. 1 (2025): 38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12032009</ArticleId><ArticleId IdType="pubmed">40281028</ArticleId></ArticleIdList></Reference><Reference><Citation>Lappalainen H., Tiula E., Uotila L., et&#xa0;al., &#x201c;Elimination Kinetics of Myoglobin and Creatine Kinase in Rhabdomyolysis: Implications for Follow&#x2010;Up,&#x201d; Critical Care Medicine 30, no. 10 (2002): 2212&#x2013;2215.</Citation><ArticleIdList><ArticleId IdType="pubmed">12394946</ArticleId></ArticleIdList></Reference><Reference><Citation>Petreski T., Piko N., Petrijan T., Dvor&#x161;ak B., Hojs R., and Bevc S., &#x201c;Statin&#x2010;Associated Necrotizing Myopathy Leading to Acute Kidney Injury: A Case Report,&#x201d; Case Reports in Nephrology and Dialysis 11, no. 2 (2021): 129&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8255745</ArticleId><ArticleId IdType="pubmed">34250030</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Y., Mo Y., and Zhang D., &#x201c;Magnesium Isoglycyrrhizinate Prevention of Chemotherapy&#x2010;Induced Liver Damage During Initial Treatment of Patients With Gastrointestinal Tumors,&#x201d; Zhonghua Gan Zang Bing Za Zhi 23, no. 3 (2015): 204&#x2013;208.</Citation><ArticleIdList><ArticleId IdType="pubmed">25938834</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q. and Zhao J., &#x201c;Therapeutic Effects of Reduced Glutathione on Liver Function, Fibrosis, and HBV DNA Clearance in Chronic Hepatitis B Patients,&#x201d; BMC Gastroenterology 25, no. 1 (2025): 68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11806808</ArticleId><ArticleId IdType="pubmed">39920583</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnham E. L., Moss M., and Ziegler T. R., &#x201c;Myopathies in Critical Illness: Characterization and Nutritional Aspects,&#x201d; Journal of Nutrition 135, no. 7 (2005): 1818S&#x2013;1823S.</Citation><ArticleIdList><ArticleId IdType="pubmed">15987872</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T. H., Wang H. C., Chang C. J., and Lee S.&#x2010;Y., &#x201c;Mitochondrial Glutathione in Cellular Redox Homeostasis and Disease Manifestation,&#x201d; International Journal of Molecular Sciences 25, no. 2 (2024): 1314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10816320</ArticleId><ArticleId IdType="pubmed">38279310</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng B., Yang Y., Li J., et&#xa0;al., &#x201c;Magnesium Isoglycyrrhizinate Alleviates Arsenic Trioxide&#x2010;Induced Cardiotoxicity: Contribution of Nrf2 and TLR4/NF&#x2010;kappaB Signaling Pathway,&#x201d; Drug Design, Development and Therapy 15 (2021): 543&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7886103</ArticleId><ArticleId IdType="pubmed">33603344</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Hou L., Guo Z., et&#xa0;al., &#x201c;Lipid Peroxidation in Osteoarthritis: Focusing on 4&#x2010;Hydroxynonenal, Malondialdehyde, and Ferroptosis,&#x201d; Cell Death Discovery 9, no. 1 (2023): 320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10465515</ArticleId><ArticleId IdType="pubmed">37644030</ArticleId></ArticleIdList></Reference><Reference><Citation>Averill&#x2010;Bates D. A., &#x201c;The Antioxidant Glutathione,&#x201d; Vitamins and Hormones 121 (2023): 109&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">36707132</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan J. G., Li Y., Yu Z., et&#xa0;al., &#x201c;Effectiveness and Economic Evaluation of Polyene Phosphatidyl Choline in Patients With Liver Diseases Based on Real&#x2010;World Research,&#x201d; Frontiers in Pharmacology 13 (2022): 806787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940240</ArticleId><ArticleId IdType="pubmed">35330831</ArticleId></ArticleIdList></Reference><Reference><Citation>Doi T., Shitara K., Naito Y., et&#xa0;al., &#x201c;Safety, Pharmacokinetics, and Antitumour Activity of Trastuzumab Deruxtecan(DS&#x2010;8201), a HER2&#x2010;Targeting Antibody&#x2010;Drug Conjugate, in Patients With Advanced Breast and Gastric or Gastro&#x2010;Oesophageal Tumours: A Phase 1 Dose&#x2010;Escalation Study,&#x201d; Lancet Oncology 18, no. 11 (2017): 1512&#x2013;1522.</Citation><ArticleIdList><ArticleId IdType="pubmed">29037983</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>